Get the Stockscreener App
26.61
1.30%
-0.35
After Hours:
26.61
Veracyte Inc stock is traded at $26.61, with a volume of 1.46M.
It is down -1.30% in the last 24 hours and down -15.20% over the past month.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.
See More
Previous Close:
$26.96
Open:
$26.73
24h Volume:
1.46M
Relative Volume:
1.42
Market Cap:
$2.08B
Revenue:
$399.58M
Net Income/Loss:
$-54.04M
P/E Ratio:
-35.48
EPS:
-0.75
Net Cash Flow:
$40.13M
1W Performance:
-2.03%
1M Performance:
-15.20%
6M Performance:
-38.04%
1Y Performance:
+26.77%
1-Day Range:
$26.32
$27.54
1-Week Range:
$26.27
$27.97
52-Week Range:
$19.73
$47.32
Veracyte Inc Stock (VCYT) Company Profile
Name
Veracyte Inc
Sector
Industry
Phone
(650) 243-6300
Address
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare VCYT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VCYT
Veracyte Inc
|
26.61 | 2.13B | 399.58M | -54.04M | 40.13M | -0.75 |
|
TMO
Thermo Fisher Scientific Inc
|
402.82 | 148.60B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
189.90 | 132.07B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
513.36 | 40.34B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
111.92 | 30.82B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
140.33 | 23.70B | 15.50B | 1.33B | 2.16B | 7.34 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-20-25 | Initiated | Craig Hallum | Buy |
| Dec-05-24 | Downgrade | Goldman | Buy → Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-16-24 | Initiated | UBS | Buy |
| Oct-10-24 | Initiated | Guggenheim | Buy |
| Feb-23-24 | Reiterated | Needham | Buy |
| Jan-18-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Nov-18-21 | Resumed | Goldman | Buy |
| Jun-15-21 | Initiated | Raymond James | Outperform |
| Feb-18-21 | Resumed | Needham | Buy |
| Jan-28-21 | Initiated | Truist | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-09-20 | Initiated | Morgan Stanley | Underweight |
| Jul-31-19 | Initiated | Lake Street | Buy |
| Jul-02-19 | Initiated | Needham | Buy |
| Nov-29-18 | Downgrade | Janney | Buy → Neutral |
| Oct-31-18 | Upgrade | Janney | Neutral → Buy |
| Nov-07-17 | Downgrade | Janney | Buy → Neutral |
| Nov-07-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-31-17 | Resumed | BTIG Research | Buy |
| Nov-14-16 | Resumed | Leerink Partners | Outperform |
| Dec-18-15 | Initiated | Cantor Fitzgerald | Buy |
| Jun-11-15 | Reiterated | Leerink Partners | Outperform |
| Nov-26-13 | Initiated | William Blair | Outperform |
View All
Veracyte Inc Stock (VCYT) Latest News
Veracyte, Inc. (VCYT) Presents Breakthrough Genomic Data to Predict Cancer Therapy Response at ASCO - MSN
Veracyte, Inc. (NASDAQ:VCYT) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Veracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance New Prostate and Bladder Cancer Research - BioSpace
Veracyte (VCYT) Showcases Findings at ASCO Annual Meeting | VCYT Stock News - GuruFocus
Veracyte to present multiple abstracts at ASCO - TipRanks
Veracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance New Prostate and Bladder Cancer Research | VCYT Stock News - GuruFocus
Veracyte Inc (VCYT) Shares Gap Down to $26.74 on May 28 - GuruFocus
Veracyte: Upgrading To Neutral (NASDAQ:VCYT) - Seeking Alpha
Captrust Financial Advisors Makes New Investment in Veracyte, Inc. (NASDAQ:VCYT) - Defense World
Scotiabank maintains Veracyte stock with $44 target - Investing.com
Deutsche Bank AG Has $3.22 Million Holdings in Veracyte, Inc. (NASDAQ:VCYT) - Defense World
Veracyte to Participate in Upcoming Investor Conferences - 01net
Veracyte to Participate in Upcoming Investor Conferences | VCYT Stock News - GuruFocus
Veracyte Stock Surges 30.9% in a Year: What's Driving the Rally? - Zacks Investment Research
BNP Paribas Financial Markets Sells 55,684 Shares of Veracyte, Inc. (NASDAQ:VCYT) - Defense World
William Blair Estimates Veracyte’s Q2 Earnings (NASDAQ:VCYT) - Defense World
Stifel Financial Corp Sells 2,211 Shares of Veracyte, Inc. (NASDAQ:VCYT) - Defense World
Veracyte projects strong Decipher and Afirma growth, targets 22.5% adjusted EBITDA margin for 2025 - MSN
Veracyte, Inc. Just Beat EPS By 260%: Here's What Analysts Think Will Happen Next - simplywall.st
Veracyte, Inc. Just Recorded A 260% EPS Beat: Here's What Analysts Are Forecasting Next - Yahoo Finance
Veracyte Stock Gains on Q1 Earnings and Revenue Beat, Gross Margin Up - Zacks Investment Research
Analysts Offer Insights on Healthcare Companies: Delcath Systems (DCTH), Veracyte (VCYT) and Inotiv (NOTV) - The Globe and Mail
Veracyte First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Decoding Veracyte Inc (VCYT): A Strategic SWOT Insight - GuruFocus
Veracyte Inc earnings beat by $0.29, revenue topped estimates - Investing.com Nigeria
Veracyte (VCYT) Target Price Lowered by UBS | VCYT Stock News - GuruFocus
What Makes Veracyte (VCYT) a New Buy Stock - Yahoo Finance
Veracyte shares target cut to $41 by Needham, keeps buy rating - Investing.com Nigeria
Veracyte, Inc. (NASDAQ:VCYT) Q1 2025 Earnings Call Transcript - Insider Monkey
UBS Adjusts Price Target for Veracyte (VCYT) Amid Growth Potential | VCYT Stock News - GuruFocus
UBS Cuts Price Target on Veracyte to $42 From $49, Keeps Buy Rating - marketscreener.com
VERACYTE, INC. SEC 10-Q Report - TradingView
Breaking Down Veracyte: 7 Analysts Share Their Views - Benzinga
Veracyte (VCYT) Target Price Lowered by Needham Analyst | VCYT Stock News - GuruFocus
Veracyte: Q1 Earnings Snapshot - Norwalk Hour
Veracyte Inc (VCYT) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansions - Yahoo Finance
Veracyte Inc (VCYT) Q1 2025 Earnings Call Highlights: Strong Rev - GuruFocus
Veracyte Reports Strong Q1 2025 Financial Growth - TipRanks
Veracyte (VCYT) Reports Strong Q1 Growth Driven by Decipher and Afirma - GuruFocus
Veracyte Announces First Quarter 2025 Financial Results - BioSpace
Veracyte Q1 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Veracyte Q1 2025 sees strong revenue growth, stock surges - Investing.com Australia
Veracyte Inc (VCYT) Q1 2025 Earnings: EPS of $0.09 Beats Estimat - GuruFocus
Veracyte (VCYT) Q1 Earnings and Revenues Beat Estimates - Yahoo Finance
Veracyte Q1 2025 slides: 18% revenue growth, transition to profitability By Investing.com - Investing.com South Africa
Veracyte Q1 2025 slides: 18% revenue growth, transition to profitability - Investing.com
Veracyte Inc Stock (VCYT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.78%
1.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):